Abstract

The primary goal of the Developmental Research Program (DRP) of the Yale SPORE in Lung Cancer (YSILC) is to identify and fund innovative pilot projects that possess translational potential for making an impact in the field of lung cancer in the areas of risk assessment; early detection; biomarkers for prognosis, therapy, and prediction; biology; and novel treatment approaches. Investigators and projects of funded developmental research projects are strongly encouraged to collaborate with other investigators within and outside of Yale, including other SPORE research communities, with the goal that these projects will evolve into independent full SPORE projects or equivalent scale studies. The objective of the YSILC DRP is to develop innovative lung cancer translational research programs. To achieve this goal, we propose the following three specific aims:
Specific Aim 1. To identify and recruit innovative pilot projects with translational potential for lung cancer.
Specific Aim 2. To support new research opportunities for lung cancer by funding innovative pilot projects.
Specific Aim 3. To enhance collaborations between SPORE full research projects and DRP investigators (current and potential) and to promote DRP projects to potential full SPORE or equivalent scale projects. Pilot projects funded by the DRP mechanism are strongly encouraged to collaborate with intra- and inter- SPORE projects. Projects making significant progress will be considered to be incorporated into a full project if there are any programmatic needs and upon agreement of the YSILC leadership in consultation with the Internal Advisory Board, External Advisory Board and NCI staff.

Public Health Relevance

PROGRAM NARRATIVE The objective of this Developmental Research Program is to foster and develop innovative lung cancer translational research programs with objectives that align with the overall goals of the Yale SPORE in Lung Cancer. Projects of the highest caliber will be sought to possibly serve as replacements for the primary SPORE projects should productivity lag or other unforeseen circumstances arise.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-02
Application #
9149460
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
2
Fiscal Year
2016
Total Cost
$47,249
Indirect Cost

  Institution

Name
Yale University
Department
Internal Medicine/Medicine
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520

  Publications

Choe, Junho; Lin, Shuibin; Zhang, Wencai et al. (2018) mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature 561:556-560
Bade, Brett C; Hyer, J Madison; Bevill, Benjamin T et al. (2018) A Patient-Centered Activity Regimen Improves Participation in Physical Activity Interventions in Advanced-Stage Lung Cancer. Integr Cancer Ther 17:921-927
Tentori, Augusto M; Nagarajan, Maxwell B; Kim, Jae Jung et al. (2018) Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab Chip 18:2410-2424
Fan, Pang-Dian; Narzisi, Giuseppe; Jayaprakash, Anitha D et al. (2018) YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proc Natl Acad Sci U S A 115:E6030-E6038
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Bondeson, Daniel P; Smith, Blake E; Burslem, George M et al. (2018) Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. Cell Chem Biol 25:78-87.e5
O'Malley, Stephanie S; Zweben, Allen; Fucito, Lisa M et al. (2018) Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial. JAMA Psychiatry 75:129-138
Wang, Jun; Sanmamed, Miguel F; Datar, Ila et al. (2018) Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3. Cell :
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40

Showing the most recent 10 out of 74 publications